Michele Nassin

Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation

Review · Frontiers in Pediatrics · 2016 · 18 citations

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial

The Lancet Haematology · 2025 · 17 citations